Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with Treatment-Resistant Depression

The tumor necrosis factor (TNF) antagonist infliximab was recently found to reduce depressive symptoms in patients with increased baseline inflammation as reflected by a plasma C-reactive protein concentration >5mg/L. To further explore predictors and targets of response to infliximab, differenti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mehta, Divya, Raison, Charles L., Woolwine, Bobbi J., Haroon, Ebrahim, Binder, Elisabeth B., Miller, Andrew H., Felger, Jennifer C.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673885/
https://ncbi.nlm.nih.gov/pubmed/23624296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbi.2013.04.004
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares